dr. apolo on cabozantinib plus nivolumab and ipilimumab in urothelial carcinoma
Published 7 years ago • 475 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
0:55
dr. apolo on the combination of cabozantinib plus nivolumab in urothelial carcinoma
-
1:13
dr. apolo on the safety of nivolumab plus cabozantinib in urothelial carcinoma
-
0:57
exploring cabozantinib with nivolumab and ipilimumab in urothelial carcinoma
-
3:31
cabozantinib–nivolumab and ipilimumab combinations show potential for gu cancers | andrea apolo
-
0:49
dr. apolo on side effects of cabozantinib plus immunotherapy agents in bladder cancer
-
0:56
dr. apolo on immunotherapy combinations with cabozantinib in genitourinary tumors
-
0:53
dr. rosenberg on dosing of nivolumab plus ipilimumab in bladder cancer
-
0:55
dr. apolo on avelumab for metastatic urothelial carcinoma
-
4:01
nivolumab–cabozantinib boosts advanced rcc outcomes | andrea apolo
-
1:09
dr. apolo on updated javelin results of avelumab in urothelial carcinoma
-
3:16
cabo-nivo or cabo-nivo-ipi for metastatic genitourinary tumors
-
0:41
dr. toni choueiri on cabozantinib and nivolumab combination in kidney cancer
-
1:00
dr. apolo on toxicity challenges with checkpoint inhibitors in bladder cancer
-
1:01
dr. andrea apolo on treatment challenges in metastatic bladder cancer
-
3:07
checkmate-214: nivolumab/ipilimumab for mrcc?
-
1:16
dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
-
7:03
ipilimumab/nivolumab for favorable-risk mrcc
-
7:08
final analysis of the atlantis cabozantinib comparison
-
1:32
dr. apolo on managing toxicities of checkpoint inhibitors in bladder cancer